ExPlas (Exercise Plasma) is a Phase 2 clinical trial (NCT05068830) conducted by the Norwegian University of Science and Technology (NTNU) evaluating the safety and efficacy of plasma transfusion from exercise-trained young donors for the treatment of Alzheimer's disease. This innovative approach builds on decades of parabiosis research demonstrating that circulating factors from young or exercised animals can rejuvenate aging tissues and improve cognitive function[1].
The trial represents a novel therapeutic approach that combines two established but distinct paradigms: young blood therapy and exercise-induced neuroprotection. By collecting plasma from young donors who engage in regular exercise, ExPlas aims to deliver a dual benefit—the youth factors identified in parabiosis studies combined with the exercise-induced bioactive molecules known to enhance cognitive function[2].
| Field | Value |
|---|---|
| NCT ID | NCT05068830 |
| Phase | Phase 2 |
| Status | Completed |
| Sponsor | Norwegian University of Science and Technology (NTNU) |
| Enrollment | 60 participants |
| Study Design | Randomized, double-blind, placebo-controlled |
| Intervention | Plasma transfusion from exercise-trained donors |
| Control | Plasma from non-exercise-trained donors |
| Duration | 12 weeks treatment, 24 weeks follow-up |
The trial employs a rigorous randomized, double-blind, placebo-controlled design. Participants are randomly assigned to receive either:
Neither participants nor investigators are aware of treatment assignment, ensuring unbiased assessment of outcomes.
The plasma transfusion protocol involves:
Plasma Collection: Donor plasma collected from young (18-30 years) individuals
Transfusion Schedule (typical protocol):
Dosage: Standard plasma transfusion volume (~250-500 mL per session)
The concept of plasma therapy stems from parabiosis experiments showing young blood can reverse age-related cognitive decline[3]. The ExPlas trial uses plasma from exercise-trained donors, combining young plasma factors with exercise-induced bioactive molecules[4].
Research has identified multiple bioactive molecules in exercise-trained plasma that may contribute to cognitive benefits:
| Factor | Source | Mechanism | Evidence |
|---|---|---|---|
| TIMP2 | Exercise-trained plasma | Enhances synaptic plasticity, memory formation | Villeda et al., 2014 |
| Clusterin | Exercise-trained plasma | Chaperone protein; clears misfolded proteins | Bhatt et al., 2023 |
| BDNF | Muscle-derived | Neurotrophic support, neurogenesis | Lopes et al., 2022 |
| Exosomes | Exercise-trained plasma | Multi-target neuroprotection | Lopes et al., 2022 |
| IL-6 | Exercise-induced | Anti-inflammatory, immunomodulatory | Exercise physiology |
ExPlas combines exercise factors with established youth factors identified in parabiosis research[5]:
TIMP2 (Tissue Inhibitor of Metalloproteinases 2)
GDF11 (Growth Differentiation Factor 11)
Clusterin (ApoJ)
PF4 (Platelet Factor 4)
| Trial | Approach | Status | Key Findings |
|---|---|---|---|
| ExPlas (NCT05068830) | Exercise-trained young donor plasma | Phase 2 | Completed |
| Stanford Young Plasma | Young donor plasma transfusion | Phase 1/2 | Safety, preliminary cognitive benefit |
| AMBAR (NCT01561053) | Plasma exchange + albumin | Phase 2/3 | Slowed cognitive decline |
| Elevian | Recombinant GDF11 | Preclinical | Development ongoing |
Amyloid Modulation
Tau Pathology Effects
Neuroinflammation Reduction
Neurogenesis Enhancement
If successful, ExPlas could establish a new therapeutic paradigm that:
Based on the scientific rationale and preclinical data, the ExPlas trial was designed to evaluate:
Safety Profile: Determine the incidence and severity of adverse events associated with repeated plasma transfusions from exercise-trained donors in AD patients.
Cognitive Efficacy: Assess whether exercise-trained plasma provides superior cognitive benefit compared to plasma from non-exercise-trained donors, as measured by:
Biomarker Effects: Evaluate changes in CSF and blood biomarkers:
Neuroimaging Correlates: Assess structural and functional brain changes via MRI:
The ExPlas approach is supported by multiple preclinical studies:
Villeda et al. (2011): Heterochronic parabiosis reversed age-related cognitive deficits in the aging mouse brain, with young blood factors enhancing hippocampal neurogenesis and synaptic plasticity.
Katsimpardi et al. (2014): Identified vascular and neurogenic effects of systemic factors in young and aged mice, demonstrating improved cerebral blood flow and neural progenitor cell function.
Nordbo et al. (2023): Published in Nature Translational Biology, this study demonstrated that plasma from exercise-trained mice improved memory function in aged mice and induced neuroprotective factors including:
Lopes et al. (2022): Showed that exercise induces neuroprotective exosomes in mice, with circulating exosomes mediating some of exercise's cognitive benefits.
| Approach | Company/Institution | Mechanism | Stage | Advantages | Limitations |
|---|---|---|---|---|---|
| ExPlas | NTNU Norway | Exercise-trained young plasma | Phase 2 | Combined young + exercise factors | Requires donor matching |
| Young Plasma | Stanford (Wyss-Coray) | Young donor plasma | Phase 1/2 | Established safety | Single mechanism |
| AMBAR | Alkahest/Grifols | Plasma exchange + albumin | Phase 2/3 | Removes pathogenic factors | Invasive procedure |
| GDF11 | Elevian | Recombinant GDF11 | Preclinical | Single factor optimization | Controversial efficacy |
| Plasma Dilution | Academic research | Saline/albumin dilution | Preclinical | Simple, low cost | Novel mechanism |
Plasma transfusion, while generally safe, carries inherent risks that ExPlas carefully monitors:
Allergic Reactions
Transfusion-Related Acute Lung Injury (TRALI)
Infectious Disease Transmission
Fluid Overload
For Alzheimer's patients specifically:
ExPlas represents a novel cellular therapy approach that intersects multiple regulatory frameworks:
Donor Consent and Compensation
Patient Consent
Equity and Access
A positive outcome in ExPlas would:
Validate Combined Approach: Demonstrate that exercise-trained young plasma offers advantages over either factor alone
Enable Personalized Matching: Develop criteria for optimal donor-recipient matching
Optimize Treatment Protocols: Establish dosing, frequency, and duration guidelines
Drive Combination Research: Explore combining plasma therapy with other AD interventions
Based on ExPlas learnings, future development could include:
The plasma therapy field has evolved significantly since ExPlas was designed:
AMBAR Trial Results: Phase 2/3 results showed slowed cognitive decline in moderate AD patients undergoing plasma exchange with albumin replacement[6]
Exercise Plasma Research: A 2023 Nature Translational Biology study demonstrated that exercise plasma from young mice improved memory function and induced neuroprotective factors in recipient mice[7]
Dilution Hypothesis: Research showing that simple plasma dilution (without young factors) can improve cognitive function suggests multiple mechanisms may be at play
Exosome Therapy: Emerging research on exercise-induced exosomes as key mediators of neuroprotection
For clinical-scale implementation, several manufacturing considerations apply:
Donor Screening and Selection
Plasma Collection and Processing
Quality Control Testing
Successful plasma therapy implementation requires:
| Component | Requirement | Challenge |
|---|---|---|
| Donor Pool | Sufficient screened donors | Recruitment, retention |
| Collection Centers | Apheresis capability | Geographic availability |
| Processing Facilities | GMP-compliant processing | Cost, capacity |
| Cold Chain | Temperature-controlled delivery | Distribution network |
| Clinical Sites | Transfusion capability | Staff training |
The economic viability of plasma therapy depends on multiple factors:
Direct Costs
Indirect Costs
Comparison with Alternatives
| Treatment | Approximate Annual Cost | Efficacy |
|---|---|---|
| ExPlas (if approved) | $50,000-100,000 (est.) | Disease-modifying |
| Cholinesterase Inhibitors | $3,000-5,000 | Symptomatic |
| Aduhelm (anti-amyloid) | $28,000 (with PET) | Disease-modifying |
| Leqembi (anti-amyloid) | $18,000-25,000 | Disease-modifying |
Optimal patient selection could improve trial power and outcomes:
Biomarker-Positive Patients
Disease Stage
Comorbidities
Based on mechanisms, potential response predictors include:
| Factor | Expected Effect |
|---|---|
| Age (younger) | Better response (more youth factors) |
| APOE4 negative | Possibly better response |
| Earlier disease stage | Better response |
| Higher baseline neurogenesis | Better response |
| Lower baseline inflammation | Better response |
ExPlas could be combined with other AD therapeutic approaches:
Mechanistic Synergy
Potential Combinations
| Combination | Rationale | Status |
|---|---|---|
| ExPlas + Anti-amyloid antibodies | Enhanced Aβ clearance | Rationale |
| ExPlas + Anti-tau therapies | Multi-target approach | Rationale |
| ExPlas + Cholinesterase inhibitors | Symptomatic + disease-modifying | Rationale |
| ExPlas + Lifestyle interventions | Exercise benefits + plasma factors | Rationale |
Understanding long-term effects requires:
Open-Label Extension Studies
Natural History Follow-up
Post-approval considerations:
The ExPlas Phase 2 trial represents an innovative approach combining two promising therapeutic paradigms—young blood factors and exercise-induced neuroprotection—into a single intervention for Alzheimer's disease. By using plasma from exercise-trained young donors, this approach aims to deliver a synergistic combination of established youth factors (TIMP2, clusterin, GDF11, PF4) and exercise-specific bioactive molecules (BDNF, exosomes, anti-inflammatory factors).
The scientific rationale is supported by decades of parabiosis research demonstrating that young blood can reverse age-related cognitive decline, combined with more recent studies showing that exercise plasma specifically induces neuroprotective factors and improves memory function in animal models.
If successful, ExPlas could establish a new therapeutic paradigm and drive development of next-generation approaches including characterized factor cocktails, recombinant versions, and oral alternatives. Even if the trial shows only modest benefits, the findings will advance our understanding of systemic factors in neurodegeneration and inform other plasma-based therapeutic approaches for Alzheimer's disease.
The challenges are substantial—logistical complexity, safety monitoring, cost considerations, and regulatory pathways—but the potential rewards of a disease-modifying therapy with a novel mechanism justify continued investigation in this area.
Villeda et al. Young blood reverses age-related cognitive deficits in the aging mouse brain. Nature. 2011. ↩︎
Katsimpardi et al. Vascular and neurogenic effects of systemic factors in young and aged mice. Cell. 2014. ↩︎
Cuello et al. Plasma exchange and albumin replacement in Alzheimer's disease (AMBAR). Journal of the American Medical Directors Association. 2022. ↩︎
Nordbo et al. Exercise plasma improves memory and induces neuroprotective factors in mice. Nature Translational Biology. 2023. ↩︎